-
Ending tuberculosis: ways forward Lancet Respir. Med. (IF 76.2) Pub Date : 2024-03-22 The Lancet Respiratory Medicine
-
Early mobilisation in the intensive care unit: shifting from navigating risks to a patient-centred approach Lancet Respir. Med. (IF 76.2) Pub Date : 2024-03-18 Hannah Wozniak, Michelle E Kho, Eddy Fan
-
Association of active mobilisation variables with adverse events and mortality in patients requiring mechanical ventilation in the intensive care unit: a systematic review and meta-analysis Lancet Respir. Med. (IF 76.2) Pub Date : 2024-03-18 Michelle Paton MPhty, Sarah Chan DPhty, Ary Serpa Neto PhD, Claire J Tipping PhD, Anne Stratton BPhty, Prof Rebecca Lane PhD, Lorena Romero MBIT, Tessa Broadley BBiomedSc, Prof Carol L Hodgson PhD
Mobilisation during critical illness is now included in multiple clinical practice guidelines. However, a large, randomised trial and systematic review have recently identified an increased probability of adverse events and mortality in patients who received early active mobilisation in the intensive care unit (ICU). We aimed to determine the effects of mobilisation compared with usual care on adverse
-
Systematic endoscopic staging of mediastinum in locally advanced NSCLC: a SEISMIC change? Lancet Respir. Med. (IF 76.2) Pub Date : 2024-03-13 Angela Botticella, Antonin Levy, Cécile Le Pechoux
-
Improving rural intensive care infrastructure in the USA Lancet Respir. Med. (IF 76.2) Pub Date : 2024-03-12 Tarun Ramesh, Michael Klompas, Hao Yu
-
Systematic endoscopic staging of mediastinum to guide radiotherapy planning in patients with locally advanced non-small-cell lung cancer (SEISMIC): an international, multicentre, single-arm, clinical trial Lancet Respir. Med. (IF 76.2) Pub Date : 2024-03-12 Prof Daniel P Steinfort PhD, Gargi Kothari MBBS, Neil Wallace MBBCh, Nicholas Hardcastle PhD, Kanishka Rangamuwa MBBCh, Edith M T Dieleman MD, Prof Percy Lee MD, Peixuan Li MBiostat, Prof Julie A Simpson PhD, Shaun Yo MBBS, Farzad Bashirdazeh MBBS, Prof Phan Nguyen PhD, Barton R Jennings MBBS, David Fielding MBBS, Laurence Crombag PhD, Prof Louis B Irving MBBS, Prof Kazuhiro Yasufuku PhD, Prof Jouke
Systematic mediastinal lymph node staging by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) improves accuracy of staging in patients with early-stage non-small-cell lung cancer (NSCLC). However, patients with locally advanced NSCLC commonly undergo only selective lymph node sampling. This study aimed to determine the proportion of patients with locally advanced NSCLC in
-
Charting a course for precision therapy trials in sepsis Lancet Respir. Med. (IF 76.2) Pub Date : 2024-03-11 Robert B Lindell, Nuala J Meyer
-
US CDC plans to relax COVID-19 isolation guidelines Lancet Respir. Med. (IF 76.2) Pub Date : 2024-02-29 Bryant Furlow
-
Trouble with promoting lung cancer screening in never-smokers – Authors' reply Lancet Respir. Med. (IF 76.2) Pub Date : 2024-02-28 Chao-Hua Chiu, Chong-Jen Yu, Gee-Chen Chang, Pan-Chyr Yang
-
Trouble with promoting lung cancer screening in never-smokers Lancet Respir. Med. (IF 76.2) Pub Date : 2024-02-28 Wayne Gao, H Gilbert Welch
-
Community-acquired pneumonia: the best candidates for clarithromycin – Authors' reply Lancet Respir. Med. (IF 76.2) Pub Date : 2024-02-28 Evangelos J Giamarellos-Bourboulis, Michael S Niederman
-
Community-acquired pneumonia: the best candidates for clarithromycin Lancet Respir. Med. (IF 76.2) Pub Date : 2024-02-28 Yiran Xu, Yun Cai
-
US EPA strengthens PM2·5 air pollution limits Lancet Respir. Med. (IF 76.2) Pub Date : 2024-02-23 Bryant Furlow
-
Reframing sepsis immunobiology for translation: towards informative subtyping and targeted immunomodulatory therapies Lancet Respir. Med. (IF 76.2) Pub Date : 2024-02-23 Prof Manu Shankar-Hari PhD, Prof Thierry Calandra PhD, Prof Miguel P Soares PhD, Prof Michael Bauer MD, Prof W Joost Wiersinga PhD, Hallie C Prescott MD, Prof Julian C Knight DPhil, Prof Kenneth J Baillie FMedSci, Lieuwe D J Bos PhD, Lennie P G Derde PhD, Prof Simon Finfer MD, Prof Richard S Hotchkiss PhD, Prof John Marshall PhD, Prof Peter J M Openshaw FMedSci, Christopher W Seymour MD, Prof Fabienne
Sepsis is a common and deadly condition. Within the current model of sepsis immunobiology, the framing of dysregulated host immune responses into proinflammatory and immunosuppressive responses for the testing of novel treatments has not resulted in successful immunomodulatory therapies. Thus, the recent focus has been to parse observable heterogeneity into subtypes of sepsis to enable personalised
-
Correction to Lancet Respir Med 2024; published online Jan 3. https://doi.org/10.1016/S2213-2600(23)00412-5 Lancet Respir. Med. (IF 76.2) Pub Date : 2024-02-21
-
A tobacco-free generation: the end goal of the endgame Lancet Respir. Med. (IF 76.2) Pub Date : 2024-02-12
-
Tuberculosis, conflict, and displacement Lancet Respir. Med. (IF 76.2) Pub Date : 2024-02-07 Talha Burki
-
Thank you to The Lancet Respiratory Medicine's clinical and statistical peer reviewers in 2023 Lancet Respir. Med. (IF 76.2) Pub Date : 2024-01-30
Abstract not available
-
Hydrocortisone plus fludrocortisone for community acquired pneumonia-related septic shock: a subgroup analysis of the APROCCHSS phase 3 randomised trial Lancet Respir. Med. (IF 76.2) Pub Date : 2024-02-02 Nicholas Heming, Alain Renault, Emmanuelle Kuperminc, Christian Brun-Buisson, Bruno Megarbane, Jean-Pierre Quenot, Shidasp Siami, Alain Cariou, Xavier Forceville, Carole Schwebel, Marc Leone, Jean-Francois Timsit, Benoît Misset, Mohamed Ali Benali, Gwenhael Colin, Bertrand Souweine, Karim Asehnoune, Emmanuelle Mercier, Loïc Chimot, Claire Charpentier, Bruno François, Thierry Boulain, Frank Petitpas
Background Glucocorticoids probably improve outcomes in patients hospitalised for community acquired pneumonia (CAP). In this a priori planned exploratory subgroup analysis of the phase 3 randomised controlled Activated Protein C and Corticosteroids for Human Septic Shock (APROCCHSS) trial, we aimed to investigate responses to hydrocortisone plus fludrocortisone between CAP and non-CAP related septic
-
Corticosteroids in septic shock secondary to community acquired pneumonia: clarity mixed with uncertainty Lancet Respir. Med. (IF 76.2) Pub Date : 2024-02-02 Balasubramanian Venkatesh, Jeremy Cohen
Abstract not available
-
First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial Lancet Respir. Med. (IF 76.2) Pub Date : 2024-01-31 Hua Zhong, Shengjie Sun, Jianhua Chen, Ziping Wang, Yanqiu Zhao, Guojun Zhang, Gongyan Chen, Ming Zhou, Jianying Zhou, Yingying Du, Lin Wu, Zhi Xu, Xiaodong Mei, Weidong Zhang, Jingdong He, Jiuwei Cui, Zhihong Zhang, Hui Luo, Weiyou Liu, Meili Sun, Baohui Han
Background Penpulimab is a novel programmed death (PD)-1 inhibitor. This study aimed to establish the efficacy and safety of first line penpulimab plus chemotherapy for advanced squamous non-small-cell lung cancer. Methods This multicentre, randomised, double-blind, placebo-controlled, phase 3 clinical trial enrolled patients with locally advanced or metastatic squamous non-small-cell lung cancer from
-
Estimated health effects from domestic use of gaseous fuels for cooking and heating in high-income, middle-income, and low-income countries: a systematic review and meta-analyses Lancet Respir. Med. (IF 76.2) Pub Date : 2024-02-01 Elisa Puzzolo PhD, Nigel Fleeman MPH, Federico Lorenzetti MSc, Fernando Rubinstein MD, Yaojie Li MSc, Ran Xing MSc, Guofeng Shen PhD, Emily Nix PhD, Michelle Maden PhD, Rebecca Bresnahan PhD, Rui Duarte PhD, Lydia Abebe PhD, Jessica Lewis PhD, Kendra N Williams PhD, Heather Adahir-Rohani MPH, Prof Daniel Pope PhD
Exposure to household air pollution from polluting domestic fuel (solid fuel and kerosene) represents a substantial global public health burden and there is an urgent need for rapid transition to clean domestic fuels. Gas for cooking and heating might possibly affect child asthma, wheezing, and respiratory health. The aim of this review was to synthesise the evidence on the health effects of gaseous
-
Health effects of gas fuels: interpreting evidence from a comprehensive meta-analysis Lancet Respir. Med. (IF 76.2) Pub Date : 2024-02-01 John Norrie
Abstract not available
-
Transitioning to gaseous and liquid fuels: a right step towards clean cooking in low-income and middle-income countries Lancet Respir. Med. (IF 76.2) Pub Date : 2024-02-01 Anindita Dutta, Christopher O Olopade
Abstract not available
-
Individualised, short-course antibiotic treatment versus usual long-course treatment for ventilator-associated pneumonia (REGARD-VAP): a multicentre, individually randomised, open-label, non-inferiority trial Lancet Respir. Med. (IF 76.2) Pub Date : 2024-01-22 Yin Mo, Suchart Booraphun, Andrew Yunkai Li, Pornanan Domthong, Gyan Kayastha, Yie Hui Lau, Ploenchan Chetchotisakd, Direk Limmathurotsakul, Paul Anantharajah Tambyah, Ben S Cooper
Background Ventilator-associated pneumonia (VAP) is associated with increased mortality, prolonged hospitalisation, excessive antibiotic use and, consequently, increased antimicrobial resistance. In this phase 4, randomised trial, we aimed to establish whether a pragmatic, individualised, short-course antibiotic treatment strategy for VAP was non-inferior to usual care. Methods We did an individually
-
Optimising antibiotic treatment duration in ventilator-associated pneumonia Lancet Respir. Med. (IF 76.2) Pub Date : 2024-01-22 Emma D Johnson, James D Chalmers
Abstract not available
-
US Senate committee investigates asthma inhaler prices Lancet Respir. Med. (IF 76.2) Pub Date : 2024-01-23 Bryant Furlow
Abstract not available
-
What is next for BCG revaccination to prevent tuberculosis? Lancet Respir. Med. (IF 76.2) Pub Date : 2024-01-22 Richard G White, Andrew J Fiore-Gartland, Willem A Hanekom, Johan Vekemans, Alberto L Garcia-Basteiro, Gavin Churchyard, Molebogeng X Rangaka, Mike Frick, Marcel A Behr, Philip C Hill, Vidya Mave
Abstract not available
-
Antibiotic prophylaxis for patients with acute brain injury Lancet Respir. Med. (IF 76.2) Pub Date : 2024-01-20 Michael Klompas
Abstract not available
-
Ceftriaxone to prevent early ventilator-associated pneumonia in patients with acute brain injury: a multicentre, randomised, double-blind, placebo-controlled, assessor-masked superiority trial Lancet Respir. Med. (IF 76.2) Pub Date : 2024-01-20 Claire Dahyot-Fizelier, Sigismond Lasocki, Thomas Kerforne, Pierre-Francois Perrigault, Thomas Geeraerts, Karim Asehnoune, Raphaël Cinotti, Yoann Launey, Vincent Cottenceau, Marc Laffon, Thomas Gaillard, Matthieu Boisson, Camille Aleyrat, Denis Frasca, Olivier Mimoz
Background Patients with acute brain injury are at high risk of ventilator-associated pneumonia (VAP). The benefit of short-term antibiotic prophylaxis remains debated. We aimed to establish the effect of an early, single dose of the antibiotic ceftriaxone on the incidence of early VAP in patients with severe brain injury who required mechanical ventilation. Methods PROPHY-VAP was a multicentre, randomised
-
Opioids bring peace to patients with IPF cough Lancet Respir. Med. (IF 76.2) Pub Date : 2024-01-15 Dominic L Sykes, Simon P Hart
Abstract not available
-
Morphine for treatment of cough in idiopathic pulmonary fibrosis (PACIFY COUGH): a prospective, multicentre, randomised, double-blind, placebo-controlled, two-way crossover trial Lancet Respir. Med. (IF 76.2) Pub Date : 2024-01-15 Zhe Wu MD, Lisa G Spencer MD, Winston Banya, John Westoby, Veronica A Tudor MD, Pilar Rivera-Ortega MD, Nazia Chaudhuri PhD, Ira Jakupovic, Brijesh Patel PhD, Muhunthan Thillai PhD, Alex West MD, Prof Marlies Wijsenbeek PhD, Prof Toby M Maher PhD, Prof Jacky A Smith PhD, Prof Philip L Molyneaux PhD
Idiopathic pulmonary fibrosis is a progressive fibrotic lung disease, with most patients reporting cough. Currently, there are no proven treatments. We examined the use of low dose controlled-release morphine compared with placebo as an antitussive therapy in individuals with idiopathic pulmonary fibrosis. The PACIFY COUGH study is a phase 2, multicentre, randomised, double-blind, placebo-controlled
-
The effectiveness of COVID-19 vaccines to prevent long COVID symptoms: staggered cohort study of data from the UK, Spain, and Estonia Lancet Respir. Med. (IF 76.2) Pub Date : 2024-01-11 Martí Català, Núria Mercadé-Besora, Raivo Kolde, Nhung T H Trinh, Elena Roel, Edward Burn, Trishna Rathod-Mistry, Kristin Kostka, Wai Yi Man, Antonella Delmestri, Hedvig M E Nordeng, Anneli Uusküla, Talita Duarte-Salles, Daniel Prieto-Alhambra, Annika M Jödicke
Background Although vaccines have proved effective to prevent severe COVID-19, their effect on preventing long-term symptoms is not yet fully understood. We aimed to evaluate the overall effect of vaccination to prevent long COVID symptoms and assess comparative effectiveness of the most used vaccines (ChAdOx1 and BNT162b2). Methods We conducted a staggered cohort study using primary care records from
-
Australia bans engineered stone to prevent silicosis Lancet Respir. Med. (IF 76.2) Pub Date : 2024-01-11 Tony Kirby
Abstract not available
-
Flooding and excessive rainfall risk respiratory health Lancet Respir. Med. (IF 76.2) Pub Date : 2024-01-09
Abstract not available
-
Risk of COVID-19-associated pulmonary aspergillosis: time for a nuanced approach to antifungal prophylaxis? Lancet Respir. Med. (IF 76.2) Pub Date : 2024-01-04 Martin Hoenigl, Juergen Prattes
Abstract not available
-
Risk factors for COVID-19-associated pulmonary aspergillosis: a systematic review and meta-analysis Lancet Respir. Med. (IF 76.2) Pub Date : 2024-01-04 Francesca Gioia, Laura N Walti, Ani Orchanian-Cheff, Shahid Husain
Background COVID-19-associated pulmonary aspergillosis (CAPA) has been reported to be an emerging and potentially fatal complication of severe COVID-19. However, risk factors for CAPA have not been systematically addressed to date. Methods In this systematic review and meta-analysis to identify factors associated with CAPA, we comprehensively searched five medical databases: Ovid MEDLINE; Ovid Embase;
-
Advancing careers in critical care medicine: the power of sponsorship and mentorship Lancet Respir. Med. (IF 76.2) Pub Date : 2024-01-05 Francesca Rubulotta
Abstract not available
-
Australia to ban disposable vapes in 2024 Lancet Respir. Med. (IF 76.2) Pub Date : 2024-01-03 Tony Kirby
Abstract not available
-
Minimally invasive thoracic surgery in Sierra Leone and Liberia Lancet Respir. Med. (IF 76.2) Pub Date : 2024-01-02 Tom M Gresnigt, Mustapha Kabba, Souheil Boubia, Rehginah Davies, Marta Lado, Mark I Kapuwa, Peter S Coleman, Trésor Mabanza, Kebede Gofer, Diego Gonzalez-Rivas
Abstract not available
-
Solid and semi-solid perspectives in thoracic surgery Lancet Respir. Med. (IF 76.2) Pub Date : 2024-01-03 Peter B Licht
Abstract not available
-
Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial Lancet Respir. Med. (IF 76.2) Pub Date : 2024-01-03 Prof Evangelos J Giamarellos-Bourboulis MD, Athanasios Siampanos MD, Amalia Bolanou MSc, Sarantia Doulou MD, Nikolaos Kakavoulis MD, Konstantinos Tsiakos MD, Sokratis Katopodis MD, Georgios Schinas MD, Lamprini Skorda MD, Zoi Alexiou MD, Konstantinos Armenis MD, Paraskevi Katsaounou MD, George Chrysos MD, Aikaterini Masgala MD, Garyphalia Poulakou MD, Nikolaos Antonakos MD, Asimina Safarika MD, Miltiades
Addition of macrolide antibiotics to β-lactam antibiotics for the treatment of patients in hospital with community-acquired pneumonia is based on results from observational studies and meta-analyses rather than randomised clinical trials. We investigated if addition of the macrolide clarithromycin to treatment with a β-lactam antibiotic in this population could improve early clinical response—the new
-
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer with radiologically pure-solid appearance in Japan (JCOG0802/WJOG4607L): a post-hoc supplemental analysis of a multicentre, open-label, phase 3 trial Lancet Respir. Med. (IF 76.2) Pub Date : 2024-01-03 Aritoshi Hattori, Kenji Suzuki, Kazuya Takamochi, Masashi Wakabayashi, Yuta Sekino, Yasuhiro Tsutani, Ryu Nakajima, Keiju Aokage, Hisashi Saji, Masahiro Tsuboi, Morihito Okada, Hisao Asamura, Kenichi Nakamura, Haruhiko Fukuda, Shun-ichi Watanabe
Background Although segmentectomy was better than lobectomy in terms of overall survival for patients with non-small-cell lung cancer (NSCLC) with a pure-solid tumour appearance on thin-section CT in the open-label, multicentre, randomised, controlled, phase 3 JCOG0802/WJOG4607L trial, the reasons why segmentectomy was associated with better overall survival were unclear. We aimed to compare the survival
-
Macrolides in community-acquired pneumonia Lancet Respir. Med. (IF 76.2) Pub Date : 2024-01-03 Grant Waterer
Abstract not available
-
Coal power plant pollution linked to deaths in the USA Lancet Respir. Med. (IF 76.2) Pub Date : 2023-12-20 Bryant Furlow
Abstract not available
-
Profiling the dysregulated immune response in sepsis: overcoming challenges to achieve the goal of precision medicine Lancet Respir. Med. (IF 76.2) Pub Date : 2023-12-21 Sara Cajander PhD, Matthijs Kox PhD, Brendon P Scicluna PhD, Markus A Weigand MD, Raquel Almansa Mora PhD, Stefanie B Flohé PhD, Prof Ignacio Martin-Loeches MD, Gunnar Lachmann MD, Prof Massimo Girardis MD, Alberto Garcia-Salido PhD, Prof Frank M Brunkhorst MD, Prof Michael Bauer MD, Prof Antoni Torres MD, Prof Andrea Cossarizza MD, Prof Guillaume Monneret PhD, Prof Jean-Marc Cavaillon PhD, Prof Manu
Sepsis is characterised by a dysregulated host immune response to infection. Despite recognition of its significance, immune status monitoring is not implemented in clinical practice due in part to the current absence of direct therapeutic implications. Technological advances in immunological profiling could enhance our understanding of immune dysregulation and facilitate integration into clinical
-
Sleep apnoea in congestive heart failure: one step forwards Lancet Respir. Med. (IF 76.2) Pub Date : 2023-12-21 Sanjay R Patel, Alexandra V Sykes, Atul Malhotra
Abstract not available
-
Adaptive servo-ventilation for sleep-disordered breathing in patients with heart failure with reduced ejection fraction (ADVENT-HF): a multicentre, multinational, parallel-group, open-label, phase 3 randomised controlled trial Lancet Respir. Med. (IF 76.2) Pub Date : 2023-12-21 T Douglas Bradley, Alexander G Logan, Geraldo Lorenzi Filho, R John Kimoff, Joaquin Durán Cantolla, Michael Arzt, Stefania Redolfi, Gianfranco Parati, Takatoshi Kasai, Mark E Dunlap, Diego Delgado, Shoichiro Yatsu, Adriana Bertolami, Rodrigo Pedrosa, George Tomlinson, Jose M Marin Trigo, Claudio Tantucci, John S Floras
Background In patients with heart failure and reduced ejection fraction, sleep-disordered breathing, comprising obstructive sleep apnoea (OSA) and central sleep apnoea (CSA), is associated with increased morbidity, mortality, and sleep disruption. We hypothesised that treating sleep-disordered breathing with a peak-flow triggered adaptive servo-ventilation (ASV) device would improve cardiovascular
-
Patient with decades of sleep apnoea history successfully treated with continuous positive airway pressure therapy Lancet Respir. Med. (IF 76.2) Pub Date : 2023-12-20 Tony Kirby
Abstract not available
-
High-resolution CT phenotypes in pulmonary sarcoidosis: a multinational Delphi consensus study Lancet Respir. Med. (IF 76.2) Pub Date : 2023-12-14 Sujal R Desai, Nishanth Sivarasan, Kerri A Johannson, Peter M George, Daniel A Culver, Anand Devaraj, David A Lynch, David Milne, Elisabetta Renzoni, Hilario Nunes, Nicola Sverzellati, Paolo Spagnolo, Robert P Baughman, Ruchi Yadav, Sara Piciucchi, Simon L F Walsh, Vasileios Kouranos, Athol U Wells
One view of sarcoidosis is that the term covers many different diseases. However, no classification framework exists for the future exploration of pathogenetic pathways, genetic or trigger predilections, patterns of lung function impairment, or treatment separations, or for the development of diagnostic algorithms or relevant outcome measures. We aimed to establish agreement on high-resolution CT (HRCT)
-
Tobacco Slave: Imperial Practices in the Modern Age Lancet Respir. Med. (IF 76.2) Pub Date : 2023-12-14 Talha Burki
Abstract not available
-
Defining cough phenotypes: chronic productive cough with obstructive lung function trajectory Lancet Respir. Med. (IF 76.2) Pub Date : 2023-12-15 Kian Fan Chung
Abstract not available
-
Association of novel adult cough subclasses with clinical characteristics and lung function across six decades of life in a prospective, community-based cohort in Australia: an analysis of the Tasmanian Longitudinal Health Study (TAHS) Lancet Respir. Med. (IF 76.2) Pub Date : 2023-12-15 Jingwen Zhang, Caroline J Lodge, E Haydn Walters, Anne B Chang, Dinh S Bui, Adrian J Lowe, Garun S Hamilton, Paul S Thomas, Chamara V Senaratna, Alan L James, Bruce R Thompson, Bircan Erbas, Michael J Abramson, Jennifer L Perret, Shyamali C Dharmage
Background Cough is a common yet heterogeneous condition. Little is known about the characteristics and course of cough in general populations. We aimed to investigate cough subclasses, their characteristics from childhood across six decades of life, and potential treatable traits in a community-based cohort. Methods For our analysis of the Tasmanian Longitudinal Health Study (TAHS), a prospective
-
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial Lancet Respir. Med. (IF 76.2) Pub Date : 2023-12-12 Mengzhao Wang, Yun Fan, Meili Sun, Yongsheng Wang, Yanqiu Zhao, Bo Jin, Ying Hu, Zhigang Han, Xia Song, Anwen Liu, Kejing Tang, Cuimin Ding, Li Liang, Lin Wu, Junzhen Gao, Jianghong Wang, Ying Cheng, Jianying Zhou, Yong He, Xiaorong Dong, Yuankai Shi
Background Sunvozertinib is an oral, irreversible, and selective tyrosine kinase inhibitor that has a favourable safety profile and encouraging antitumour activity, as shown in phase 1 studies of patients with heavily pretreated non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutation (exon20ins). We aimed to assess the antitumour efficacy of sunvozertinib in patients with platinum-pretreated
-
Sunvozertinib: the next candidate of TKI for NSCLC Lancet Respir. Med. (IF 76.2) Pub Date : 2023-12-12 Hidetoshi Hayashi
Abstract not available
-
Patterns of respiratory infections after COVID-19 Lancet Respir. Med. (IF 76.2) Pub Date : 2023-12-12
Abstract not available
-
Cystic fibrosis: a call for papers for ECFS 2024 Lancet Respir. Med. (IF 76.2) Pub Date : 2023-12-12 Emma Grainger
Abstract not available
-
Pioneering a paradigm shift in asthma management: remission as a treatment goal Lancet Respir. Med. (IF 76.2) Pub Date : 2023-12-07 Marek Lommatzsch, Roland Buhl, G Walter Canonica, Christian Domingo Ribas, Hiroyuki Nagase, Guy G Brusselle, David J Jackson, Ian D Pavord, Stephanie Korn, Katrin Milger, Christian Taube, J Christian Virchow
Abstract not available
-
Individualised perioperative ventilation in one-lung anaesthesia? Lancet Respir. Med. (IF 76.2) Pub Date : 2023-12-05 Pádraig M Buggy, Donal J Buggy
Abstract not available
-
Individualised, perioperative open-lung ventilation strategy during one-lung ventilation (iPROVE-OLV): a multicentre, randomised, controlled clinical trial Lancet Respir. Med. (IF 76.2) Pub Date : 2023-12-05 Carlos Ferrando, Albert Carramiñana, Patricia Piñeiro, Lucia Mirabella, Savino Spadaro, Julián Librero, Fernando Ramasco, Gaetano Scaramuzzo, Oriol Cervantes, Ignacio Garutti, Ana Parera, Marta Argilaga, Gracia Herranz, Carmen Unzueta, Marc Vives, Kevin Regi, Marta Costa-Reverte, María Sonsoles Leal, Jesús Nieves-Alonso, Esther García, Stefania Spiga
Background It is uncertain whether individualisation of the perioperative open-lung approach (OLA) to ventilation reduces postoperative pulmonary complications in patients undergoing lung resection. We compared a perioperative individualised OLA (iOLA) ventilation strategy with standard lung-protective ventilation in patients undergoing thoracic surgery with one-lung ventilation. Methods This multicentre